

Press Release

FOR IMMEDIATE RELEASE

30 APRIL, 2026

Laurus Labs Announces Full Year FY26 Results

Revenues at ₹ 6,813 Cr; EBITDA at ₹ 1,826 Cr, 26.8% margins

Hyderabad, April 30, 2026: Laurus Labs Ltd. (**Laurus BSE: 540222, NSE: LAURUSLABS, ISIN: INE947Q01028**), a leading research and development driven pharmaceutical and biotech company in India announces its Q4 & Full Year FY26 results.

Financial Summary

[₹ Crore] except EPS amounts	4Q FY26	4Q FY25	Y-o-Y	FY26	FY25	Y-o-Y
Revenues	1,812	1,720	5%	6,813	5,554	23%
Gross Margins	61.4%	54.5%	+6.9%	60.4%	55.4%	+5.0%
EBITDA	523	477	+10%	1,826	1,115	+64%
EBITDA Margins	28.9%	27.7%	+1.2%	26.8%	20.1%	+6.7%
PBT	361	312	+16%	1,182	484	+144%
Net Profit	279	234	+19%	889	358	+148%
EPS (Diluted)	5.2	4.3	+21%	16.4	6.6	+148%

Dr. Satyanarayana Chava, Founder & Chief Executive Officer commented;

“We significantly accelerated our performance in FY 26, delivering strong revenue growth and expanded profitability, backed by successful commercial supplies for NCE programs, new launches ramp-up and sustained leadership in Anti-retroviral segment.

The transformation of our portfolio is well underway, and momentum is building. We are making significant investments in novel technologies, scale and strengthening integrated capabilities offerings towards laying foundation for future growth. In the face of macro-economic volatility, our business model has proven resilient and we remain well positioned to execute on our growth strategy with continued progress on our EHS/ESG initiatives.”

Corporate Office

Plot No.103, Road No.1, Jubilee Hills, Hyderabad 500033, Telangana, India
T +91 40 6659 4333, 2342 0500/501 F +91 40 6659 4320

Registered Office

Laurus Enclave, Plot Office 01, E.Bonangi Village, Parawada Mandal, Anapalli District – 531021, Andhra Pradesh, India
CIN : L24239AP2005PLC047518, T +91 891 682 1101, 1102, F +91 891 682 1103, E info@lauruslabs.com, W lauruslabs.com

V V Ravi Kumar, Executive Director & Chief Financial Officer commented;

We sustained strong operating performance for the current quarter Q4 FY 26. We have achieved revenues of ₹ 1,812 Cr, representing 5% growth and EBITDA of ₹ 523 Cr, representing 10% growth over the previous year Q4 FY 25. The EBITDA margins were strong at 28.9%, supported by continuing operating leverage.

Overall, we reported strong FY 26 performance, reflecting continued robust demand for integrated offering across CDMO and Affordable Medicines business. We achieved ₹ 6,813 Cr in revenues, representing 23% growth and EBITDA of ₹ 1,826 Cr, representing 64% growth, resulting in 26.8% EBITDA margins marking significant >6% pts improvement over the previous year. Gross margins improved by over 5% pts to 60.4% due to favorable CDMO mix.

These results demonstrate the strength of our business and give us confidence in our outlook. Our Balance sheet remain well positioned to support key CAPEX program ahead with continued focus on operational excellence.

Divisional Revenue Performance

[₹ Crore]	4Q FY26	4Q FY25	Y-o-Y	FY26	FY25	Y-o-Y
CDMO	589	490	20%	2,080	1,534	36%
Small molecules	524	461	14%	1,896	1,374	38%
Bio	65	29	124%	184	160	15%
Affordable Medicines (Generics)	1,223	1,230	-1%	4,733	4,020	18%
API	772	686	13%	2,746	2,438	13%
FDF	451	544	-17%	1,987	1,582	26%
Total Revenues	1,812	1,720	5%	6,813	5,554	23%
ARV Revenues*	683	803	-15%	2,807	2,559	10%

* Includes API and Formulation (FDF) combined revenues

Summary Highlights:

- Robust FY26 performance; ₹ 6,813 Cr Revenues and 23% revenues growth. Performance driven by strong growth in CDMO division, sustained demand across complex chemistry platforms supported by growth in Affordable Medicine division
- ₹1,826 Cr EBITDA with a margin of 26.8%, increased by 6.7% pts, supported by robust operational execution and operating leverage. Gross margins expansion of over 5.0% pts to 60.4% on better product mix.
- Q4 Revenues ₹ 1,812 Cr; +5% revenue growth, ₹ 523 Cr EBITDA; +10% growth resulted in a margin of 28.9%, Gross margins were at 61.4%
- FY26 CAPEX at 16% of Sales with continued advancement in on-going investment program to enable future growth across technologies. Capex Intensity to increase over FY27-28 to support growth projects across Small molecule (Human & Animal health), Fermentation, Peptides, and Gene therapy/ADC
- Declared second interim dividend of ₹ 1.2 per share during Q4 FY26

Divisional Highlights:

CDMO – Small molecules

- CDMO business reported revenues of ₹ 1,896 Cr, during FY26; increased by 38% from late stage pipeline, commercial NCE API supplies, ramp-up of the growth projects
- Q4 Revenues of ₹ 524 Cr; increased by 14% Y/Y
- Sustained clinical and commercial contracting across technologies and sites driving good growth outlook
- Advancing on commercial peptides manufacturing capability
- Pipeline momentum remained healthy: >125 Active pipeline projects across Human health, Animal health and Crop science
- Crossed 8200kL of reactor volumes in FY26. We are continuing CAPEX in large-scale API & fermentation capacity in Vizag

BIO – Large molecules

- Bio business reported revenues of ₹ 184 Cr, during FY26; increased by 15%. We reported healthy growth through revenue diversification
- Continued pipeline progress on larger Global accounts across AOF and CDMO business
- Q4 Revenues of ₹ 65 Cr; increased by 124% Y/Y
- Expanding bio-catalysis application across small molecule clinical and commercial API projects

Affordable Medicines (Generics)

- Affordable Medicines division reported revenues of ₹ 4,733 Cr, during FY26, increased by 18%
- Strong performance driven by volume growth in ARV portfolio and ramp up of the select molecules in US and EU region
- Q4 Revenues of ₹ 1,223 Cr; decreased by 1% Y/Y
- Continued investment in Capacities, integrated CMO, and expanding footprint across Developed market and Emerging market to support FY27
- KRKA JV: FDF facility construction work going as per plan; Phase-1 manufacturing blocks to be ready by mid-2027
- Product filings update:
 - DMF filings: Cumulatively, 92 DMFs filed till date
 - Developed market FDF filings: 7 product dossiers filed and a total of 6 approvals received (including Tentative approvals) in FY26. Cumulatively, 94 products filed till date

Quality & ESG Highlights:

- We completed 132 Quality audits in FY26. Company has successfully passed audit inspections without critical findings
- Laurus was listed consecutively in S&P Global Sustainability Yearbook for both 2024 and 2025
- Committed to the United Nations Global Compact (UNGC) in support of its ten sustainability principles

Earnings Conference Call

The company will organize a conference call on Thursday, April 30, 2026 at 5:00 p.m. IST to discuss Q4 & Full Year FY26 results followed by an interactive Q&A session from participants. All participants may join the call by dialing below numbers OR by using Diamond Pass link

Conference Dial-in	
Universal Dial-In	+91 22 6280 1384
India Local access Number	+91 22 7115 8285
Singapore	+800 101 2045
Hong Kong	+800 964 448
USA	+1 866 746 2133
UK	+0 808 101 1573
Express Join with Diamond Pass	Click here to register

Transcript of the conference call will be available on the Company's website: www.lauruslabs.com

END

Media Relations

Karthik C
T +91 40 3980 4380 | 9030088669
mediarelations@lauruslabs.com

Investors Relations

Vivek Kumar
T +91 40 3980 4366
investorrelations@lauruslabs.com

About Laurus Labs

Laurus Labs is a research-driven pharmaceutical and biotechnology company committed to improving global health. It holds a leadership position in developing and manufacturing select Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDF) across anti-retroviral, oncology, cardiovascular, and gastro therapeutics. With strong backward integration and stringent quality standards, Laurus has built a solid reputation for high-quality, innovative solutions.

The company offers end-to-end Contract Development and Manufacturing Organization (CDMO) services, supporting innovators from early-stage development to commercial production. Laurus employs over 8,126 people, including 3,134+ scientists, and operates 15 facilities approved by global regulators like the USFDA, WHO, EMA, and more. Its “Smart and Green” chemistry approach drives sustainable manufacturing and operational excellence.

Laurus Labs generated ₹6,813 crore in revenue in FY2026 and is listed on the BSE and NSE. The company is a certified Great Place to Work and holds a “BBB” MSCI ESG rating, reflecting its commitment to transparency, integrity, and ESG principles. It is widely recognized for upholding environmental stewardship and ethical business practices.

Expanding beyond small molecules, Laurus is enhancing its capabilities in biotechnology, large molecules, cell, and gene therapies. Its diversified offerings span human and animal health APIs, intermediates, crop science, and specialty ingredients for nutrition and cosmetics. Guided by the principle “Chemistry for Better Living,” Laurus remains dedicated to advancing science for better global health outcomes. Corporate Identification No: L24239AP2005PLC047518.

For more information visit www.lauruslabs.com

Follow @ Laurus Labs on [LinkedIn](#) | [Twitter](#) | [Facebook](#) | [Instagram](#)

Disclaimer

Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Laurus Labs Limited (Laurus) will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.